M&A

Amneal to buy generic pharmaceuticals provider AvKARE for $340m
Amneal to buy generic pharmaceuticals provider AvKARE for $340m
Pharmaceutical Business Review
Amneal
generics
M&A
AvKARE
Flag link:
2 Top Biotech Buyout Candidates
2 Top Biotech Buyout Candidates
Motley Fool
M&A
Amarin
Vascepa
Aurinia Pharmaceuticals
voclosporin
Flag link:
Justice Department Will Reportedly Review Google’s $2.1 Billion Fitbit Acquisition
Justice Department Will Reportedly Review Google’s $2.1 Billion Fitbit Acquisition
Forbes
DOJ
Google
Fitbit
wearables
devices
M&A
Flag link:
For an 'acquisitive' Gilead, 2020 will be key test for CAR-T plans
For an 'acquisitive' Gilead, 2020 will be key test for CAR-T plans
Biopharma Dive
M&A
Gilead Sciences
Kite
Flag link:
Sanofi Is Paying a 172% Premium to Buy Synthorx -- and It Sounds Like a Good Deal for Both
Sanofi Is Paying a 172% Premium to Buy Synthorx -- and It Sounds Like a Good Deal for Both
Motley Fool
Sanofi
immuno-oncology
M&A
Synthorx
Flag link:
Roche extends tender offer for Spark Therapeutics, again
Roche extends tender offer for Spark Therapeutics, again
Marketwatch
Roche
Spark Therapeutics
M&A
Flag link:
Disruptor of the Year: The Federal Trade Commission
Disruptor of the Year: The Federal Trade Commission
Biopharma Dive
FTC
M&A
Roche
Spark Therapeutics
Flag link:
Merck to acquire ArQule for $20 per share in cash or about $2.7 billion
Merck to acquire ArQule for $20 per share in cash or about $2.7 billion
Marketwatch
Merck
M&A
Arqule
oncology
Flag link:
Deal of the Year: Bristol-Myers Squibb buys Celgene
Deal of the Year: Bristol-Myers Squibb buys Celgene
Biopharma Dive
M&A
Bristol-Myers Squibb
Celgene
Flag link:
Sanofi to acquire Synthorx for $2.5 billion
Sanofi to acquire Synthorx for $2.5 billion
Marketwatch
Sanofi
M&A
Synthorx
Flag link:
Alexion shoots down 'proactive' sale demand from activist investor
Alexion shoots down 'proactive' sale demand from activist investor
Fierce Pharma
Alexion
investors
M&A
Flag link:
Why Sorrento Therapeutics Was Right to Reject Takeover Bids With A 245% Premium
Why Sorrento Therapeutics Was Right to Reject Takeover Bids With A 245% Premium
Motley Fool
Sorrento Therapeutics
M&A
ZTlido
Flag link:
Lilly puts its cancer future in Loxo's hands
Lilly puts its cancer future in Loxo's hands
Biopharma Dive
Eli Lilly
Loxo Oncology
M&A
cancer
R&D
oncology
Flag link:
Gene Therapy M&A Appetite Provides Lift After Audentes Deal
Gene Therapy M&A Appetite Provides Lift After Audentes Deal
Yahoo/Bloomberg
gene therapy
Astellas
Audentes Therapeutics
M&A
Novartis
Medicines Company
Flag link:
Is Clovis Oncology Really a Buyout Candidate?
Is Clovis Oncology Really a Buyout Candidate?
Motley Fool
Clovis Oncology
M&A
Rubraca
oncology
Flag link:
Why Novartis's $9.7 Billion Purchase of The Medicines Company Is Bad News for Amgen
Why Novartis's $9.7 Billion Purchase of The Medicines Company Is Bad News for Amgen
Motley Fool
Novartis
Medicines Company
M&A
inclisiran
Flag link:
Japan's Astellas to buy Audentes for $3 billion in gene therapy push
Japan's Astellas to buy Audentes for $3 billion in gene therapy push
Reuters
Astellas
M&A
gene therapy
Audentes Therapeutics
Flag link:
Veloxis wins $1.3B buyout deal, and the new owner plans to follow up with new deals
Veloxis wins $1.3B buyout deal, and the new owner plans to follow up with new deals
Endpoints
Asahi Kasei
Veloxis Pharmaceuticals
M&A
organ rejection
Envarsus XR
kidney transplants
Flag link:
Why Novartis Is Buying The Medicines Company For $9.7 Billion
Why Novartis Is Buying The Medicines Company For $9.7 Billion
Forbes
Novartis
Medicines Company
M&A
inclisiran
Flag link:
Amarin for $20B? Novartis' MedCo deal drives fresh buyout rumors for Vascepa's maker
Amarin for $20B? Novartis' MedCo deal drives fresh buyout rumors for Vascepa's maker
Fierce Pharma
Amarin
M&A
Novartis
Medicines Company
Gilead Sciences
Flag link:

Pages